// March 01, 2024
Innovating for Individual Care: The Impact of USP on Personalized Medicine
In 2022, personalized medicines (PM) made up more than 34% of new therapeutics approved by the Fo
In 2022, personalized medicines (PM) made up more than 34% of new therapeutics approved by the Fo
India is often referred to as the ‘pharmacy of the world’ and is undeniably the leading manufactu
USP’s supplier qualification standard became official on Aug.